Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics.
Four anticancer drugs with cell cycle phase-specific characteristics (azathioprine, cytosine arabinoside, hydroxyurea, and vincristine) were individually used to treat 12 patients with multiple myeloma in partial remission (ie, greater than or equal to 50% reduction in tumor cell number) after cell cycle nonspecific chemotherapy. In six of eight patients vincristine induced further statistically significant reduction in total body myeloma cell number (24%-60% tumor cell reductions), whereas, azathiprine had lesser activity. Cytosine arabinoside and hydroxyurea were unsuccessful and excessively toxic chemotherapeutic agents in this setting, although optimal dosing schedules were difficult to achieve because they caused moderately severe bone marrow suppression. We conclude that vincristine is a useful cytoreductive agent for multiple myeloma and should be added to cell cycle nonspecific agents for the treatment of this disease.
D000477:Alkylating Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D003561:Cytarabine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D012075:Remission, Spontaneous; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use*
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D003561:Cytarabine; D014750:Vincristine; D001379:Azathioprine; D006918:Hydroxyurea